The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million for drugs that it hopes will challenge Vertex ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

To read more letters to the editor, go to oregonlive.com/opinion.

Latigo Biotherapeutics CEO Nima Farzan stated: “The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust ...

Ark is already conducting studies with this new class of pain medication, leveraging its strong infrastructure, experienced staff, and extensive access to patient populations. With strong community ...